

Carlo Tondini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7485226/publications.pdf>

Version: 2024-02-01

118
papers

5,796
citations

117571

34
h-index

79644

73
g-index

121
all docs

121
docs citations

121
times ranked

8276
citing authors

#	ARTICLE	IF	CITATIONS
1	Time-Dependent COVID-19 Mortality in Patients With Cancer. <i>JAMA Oncology</i> , 2022, 8, 114.	3.4	50
2	A Remote Monitoring System to Optimize the Home Management of Oral Anticancer Therapies (ONCO-TreC): Prospective Training and Validation Trial. <i>Journal of Medical Internet Research</i> , 2022, 24, e27349.	2.1	2
3	COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry. <i>Journal of the National Cancer Institute</i> , 2022, 114, 979-987.	3.0	14
4	Persistence of long-term COVID-19 sequelae in patients with cancer: An analysis from the OnCovid registry. <i>European Journal of Cancer</i> , 2022, 170, 10-16.	1.3	11
5	Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study. <i>Lancet Oncology</i> , The, 2022, 23, 865-875.	5.1	50
6	The use of genomic tests in patients with breast cancer in Lombardy: a successful healthcare model. <i>Tumori</i> , 2021, 107, 166-170.	0.6	5
7	Prevalence and Clinical Impact of SARS-CoV-2 Silent Carriers Among Actively Treated Patients with Cancer During the COVID-19 Pandemic. <i>Oncologist</i> , 2021, 26, 341-347.	1.9	7
8	Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspective. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110422.	1.4	4
9	Validation of the Role of Thrombin Generation Potential by a Fully Automated System in the Identification of Breast Cancer Patients at High Risk of Disease Recurrence. <i>TH Open</i> , 2021, 05, e56-e65.	0.7	9
10	Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score. , 2021, 9, e002277.		30
11	Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study. <i>European Journal of Cancer</i> , 2021, 150, 190-202.	1.3	37
12	Analysis of Italian BRCA1/2 Pathogenic Variants Identifies a Private Spectrum in the Population from the Bergamo Province in Northern Italy. <i>Cancers</i> , 2021, 13, 532.	1.7	8
13	Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study. <i>Lancet Oncology</i> , The, 2021, 22, 1669-1680.	5.1	73
14	Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT. <i>Journal of Clinical Oncology</i> , 2020, 38, 1293-1303.	0.8	93
15	Cancer Risks Associated With Germline <i>PALB2</i> Pathogenic Variants: An International Study of 524 Families. <i>Journal of Clinical Oncology</i> , 2020, 38, 674-685.	0.8	270
16	Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer. <i>Cancer Discovery</i> , 2020, 10, 1465-1474.	7.7	151
17	Thrombin generation predicts early recurrence in breast cancer patients. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2220-2231.	1.9	17
18	Prospective observational study on the impact of the 21-gene assay on treatment decisions and resources optimization in breast cancer patients in Lombardy: The BONDx study. <i>Breast</i> , 2020, 52, 1-7.	0.9	8

#	ARTICLE	IF	CITATIONS
19	Thrombotic biomarkers for risk prediction of malignant disease recurrence in patients with early stage breast cancer. <i>Haematologica</i> , 2020, 105, 1704-1711.	1.7	21
20	Homologous recombination DNA repair defects in PALB2-associated breast cancers. <i>Npj Breast Cancer</i> , 2019, 5, 23.	2.3	39
21	Italian Cohort of the Nivolumab EAP in Squamous NSCLC: Efficacy and Safety in Patients With CNS Metastases. <i>Anticancer Research</i> , 2019, 39, 4265-4271.	0.5	33
22	Cobimetinib in malignant melanoma: how to MEK an impact on long-term survival. <i>Future Oncology</i> , 2019, 15, 967-977.	1.1	10
23	The spectrum of <i>BRCA1</i> and <i>BRCA2</i> pathogenic sequence variants in Middle Eastern, North African, and South European countries. <i>Human Mutation</i> , 2019, 40, e1-e23.	1.1	34
24	Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial. <i>Breast Cancer Research</i> , 2019, 21, 71.	2.2	19
25	Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 105-114.	0.8	72
26	Prognostic impact of regression in patients with primary cutaneous melanoma >1mm in thickness. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 99-105.e5.	0.6	19
27	Late-occurring toxicity induced by an immune checkpoint blockade in adjuvant treatment of a stage III melanoma patient. <i>European Journal of Cancer</i> , 2018, 95, 130-132.	1.3	23
28	Two Missense Variants Detected in Breast Cancer Proband Preventing BRCA2-PALB2 Protein Interaction. <i>Frontiers in Oncology</i> , 2018, 8, 480.	1.3	11
29	Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. <i>Lancet Oncology</i> , 2018, 19, 1385-1393.	5.1	342
30	PO-0850: Full-Dose Breast Intraoperative Radiotherapy In The Elderly: A Single Center Experience. <i>Radiotherapy and Oncology</i> , 2018, 127, S444-S445.	0.3	0
31	Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 122-137.	13.9	448
32	Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial. <i>Annals of Oncology</i> , 2018, 29, 1748-1754.	0.6	76
33	Absolute improvements in freedom from distant recurrence with adjuvant endocrine therapies for premenopausal women with hormone receptor-positive (HR+) HER2-negative breast cancer (BC): Results from TEXT and SOFT.. <i>Journal of Clinical Oncology</i> , 2018, 36, 503-503.	0.8	15
34	Rationale for New Checkpoint Inhibitor Combinations in Melanoma Therapy. <i>American Journal of Clinical Dermatology</i> , 2017, 18, 597-611.	3.3	11
35	Optimisation and validation of a remote monitoring system (Onco-TreC) for home-based management of oral anticancer therapies: an Italian multicentre feasibility study. <i>BMJ Open</i> , 2017, 7, e014617.	0.8	25
36	P3.02c-092 Nivolumab in Multi-Treated Patients with Advanced Sq-NSCLC: Data from the Italian Cohort of Expanded Access Programme (EAP). <i>Journal of Thoracic Oncology</i> , 2017, 12, S1334-S1335.	0.5	0

#	ARTICLE	IF	CITATIONS
37	Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT. <i>Annals of Oncology</i> , 2017, 28, 2225-2232.	0.6	56
38	Mitotic rate correlates with sentinel lymph node status and outcome in cutaneous melanoma greater than 1 millimeter in thickness: A multi-institutional study of 1524 cases. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 264-273.e2.	0.6	41
39	Breast cancer electron intraoperative radiotherapy: assessment of preoperative selection factors from a retrospective analysis of 758 patients and review of literature. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 261-271.	1.1	9
40	Abstract P4-21-42: MetaPHER phase IIIb multicenter, open-label, single-arm safety study of subcutaneous trastuzumab in combination with pertuzumab and docetaxel in patients with HER2-positive advanced breast cancer: First results. , 2017, , .		3
41	A phase II trial of the CDK4/6 inhibitor palbociclib (P) as single agent or in combination with the same endocrine therapy (ET) received prior to disease progression, in patients (pts) with hormone receptor positive (HR+) HER2 negative (HER2 ⁻) metastatic breast cancer (mBC) (TREnd trial).. <i>Journal of Clinical Oncology</i> , 2017, 35, 1002-1002.	0.8	14
42	Abstract P2-03-01: Mutational landscape of breast cancers from PALB2 germline mutation carriers. , 2017, , .		0
43	Abstract P2-09-05: 12 years' median follow up (MFLU) of BIG 1-98: Adjuvant letrozole, tamoxifen and their sequence for postmenopausal women with endocrine responsive early breast cancer. , 2017, , .		0
44	Abstract P4-22-17: Safety of the combination of everolimus plus exemestane in the Italian cohort of patients enrolled in the expanded access "BALLETT" study. , 2017, , .		0
45	Uncommon epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer and sensitivity to EGFR tyrosine kinase inhibitors, a two centers experience. <i>Annals of Oncology</i> , 2016, 27, iv9.	0.6	1
46	Surgical Resection Margins after Breast-Conserving Surgery: Senonetwork Recommendations. <i>Tumori</i> , 2016, 102, 284-289.	0.6	14
47	Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 1601-1610.	0.8	100
48	Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor ⁺ Positive, Human Epidermal Growth Factor Receptor 2 ⁻ Negative Early Breast Cancer: TEXT and SOFT Trials. <i>Journal of Clinical Oncology</i> , 2016, 34, 2221-2231.	0.8	148
49	Thrombophilic status may predict prognosis in patients with metastatic BRAFV600-mutated melanoma who are receiving BRAF inhibitors. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 1254-1256.e4.	0.6	9
50	Haplotype analyses of the c.1027C>T and c.2167_2168delAT recurrent truncating mutations in the breast cancer-predisposing gene PALB2. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 121-129.	1.1	11
51	Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor ⁻ Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00. <i>Journal of Clinical Oncology</i> , 2016, 34, 3400-3408.	0.8	65
52	Endocrine therapy in post-menopausal women with metastatic breast cancer: From literature and guidelines to clinical practice. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 100, 57-68.	2.0	15
53	Abstract 134: Mutational landscape of breast cancers from PALB2 germline mutation carriers. , 2016, , .		0
54	1872 Moving beyond clinical trials: A real world multicenter Italian experience with albumin-bounded Paclitaxel (nab-Paclitaxel) in metastatic breast cancer. <i>European Journal of Cancer</i> , 2015, 51, S290.	1.3	1

#	ARTICLE	IF	CITATIONS
55	<i>FANCM</i>c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor. <i>Human Molecular Genetics</i> , 2015, 24, 5345-5355.	1.4	91
56	Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. <i>Lancet Oncology</i> , The, 2015, 16, 848-858.	5.1	145
57	Abstract S3-09: Patient-reported endocrine symptoms, sexual functioning and quality of life (QoL) in the IBCSG SOFT trial: Adjuvant treatment with tamoxifen (T) alone versus tamoxifen plus ovarian function suppression (OFS) in premenopausal women with hormone receptor-po. , 2015, , .		2
58	Measurement of Thrombin Generation Is a Positive Predictive Biomarker of Venous Thromboembolism (VTE) in Metastatic Cancer Patients Enrolled in the Hypercan Study. <i>Blood</i> , 2015, 126, 654-654.	0.6	2
59	Eribulin mesylate in heavily pretreated metastatic breast cancer patients: current practice in an Italian community hospital. <i>Future Oncology</i> , 2014, 10, 233-239.	1.1	19
60	Breast-Cancer Risk in Families With Mutations in PALB2. <i>Obstetrical and Gynecological Survey</i> , 2014, 69, 659-660.	0.2	1
61	PALB2 sequencing in Italian familial breast cancer cases reveals a high-risk mutation recurrent in the province of Bergamo. <i>Genetics in Medicine</i> , 2014, 16, 688-694.	1.1	25
62	Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences. <i>Breast Cancer Research and Treatment</i> , 2014, 144, 321-329.	1.1	7
63	Breast-Conservative Surgery With and Without Radiotherapy in Patients Aged 55â€“75 Years With Early-Stage Breast Cancer: A Prospective, Randomized, Multicenter Trial Analysis After 108 Months of Median Follow-up. <i>Annals of Surgical Oncology</i> , 2014, 21, 408-415.	0.7	44
64	Breast-Cancer Risk in Families with Mutations in <i>PALB2</i>. <i>New England Journal of Medicine</i> , 2014, 371, 497-506.	13.9	745
65	Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer. <i>New England Journal of Medicine</i> , 2014, 371, 107-118.	13.9	621
66	Prophylaxis strategy to prevent HBV-reactivation in oncologic immunosuppressed patients: Results of guidelines-based on-field practice. <i>Digestive and Liver Disease</i> , 2014, 46, e51.	0.4	0
67	Patient-reported endocrine symptoms, sexual functioning, and quality of life (QoL) in the IBCSG TEXT and SOFT trials: Adjuvant treatment with exemestane (E) plus ovarian function suppression (OFS) versus tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC). <i>Journal of Clinical Oncology</i> , 2014, 32, 557-557.	0.8	3
68	Characterization of an Italian Founder Mutation in the RING-Finger Domain of BRCA1. <i>PLoS ONE</i> , 2014, 9, e86924.	1.1	24
69	Hypercoagulation Screening As a Marker of Thrombosis and Poor Disease Prognosis in Cancer Patients: The Hypercan Prospective Study. <i>Blood</i> , 2014, 124, 586-586.	0.6	2
70	Hepatitis B in immunosuppressed cancer patients: Pathogenesis, incidence and prophylaxis. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 87, 12-27.	2.0	19
71	PO62 DIFFERENT PATTERNS OF TREATMENT WITH ALBUMIN-BOUND PACLITAXEL (NAB-PACLITAXEL) FOR TARGETED CHEMOTHERAPY IN METASTATIC BREAST CANCER: A MULTICENTER ITALIAN EXPERIENCE ON 125 WOMEN. <i>Breast</i> , 2013, 22, S41.	0.9	0
72	Abstract S5-06: Epirubicin and cyclophosphamide (EC) followed by paclitaxel (T) versus fluorouracil, epirubicin and cyclophosphamide (FEC) followed by T, all given every 3 weeks or 2 weeks, in node-positive early breast cancer (BC) patients (pts). Final results of the gruppo Italiano mammella (GIM)-2 randomized phase III study. , 2013, , .		7

#	ARTICLE	IF	CITATIONS
73	Adjuvant therapy in breast cancer and venous thromboembolism. <i>Thrombosis Research</i> , 2012, 130, S66-S70.	0.8	16
74	Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 283-289.	1.1	101
75	Association of Socioeconomic Status With Breslow Thickness and Disease-Free and Overall Survival in Stage I-II Primary Cutaneous Melanoma. <i>Mayo Clinic Proceedings</i> , 2011, 86, 113-119.	1.4	28
76	Type and trends in outcomes research in breast cancer between 2000 and 2007. <i>Annals of Oncology</i> , 2011, 22, 2160-2165.	0.6	3
77	Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues. <i>Breast</i> , 2011, 20, 176-183.	0.9	42
78	The impact of thromboprophylaxis on cancer survival: focus on pancreatic cancer. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 579-588.	1.1	8
79	International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). <i>Journal of the National Cancer Institute Monographs</i> , 2011, 2011, 147-151.	0.9	61
80	Bone mineral density (BMD) in participants (pts) of trial BIG 1-98 comparing adjuvant letrozole (L) versus tamoxifen (T) or their sequence.. <i>Journal of Clinical Oncology</i> , 2011, 29, 516-516.	0.8	2
81	Clinical activity and cardiac tolerability of non-pegylated liposomal doxorubicin in breast cancer: a synthetic review. <i>Tumori</i> , 2011, 97, 690-2.	0.6	15
82	Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial. <i>Annals of Oncology</i> , 2010, 21, 871-876.	0.6	76
83	Relationship between socio-economic status and education grade on Breslow thickness and ulceration in clinical stage I-II AJCC skin melanoma: Analysis from a single institution prospectively collected data base.. <i>Journal of Clinical Oncology</i> , 2010, 28, e19004-e19004.	0.8	0
84	Conservative surgery with and without radiotherapy in elderly patients with early-stage breast cancer: A prospective randomised multicentre trial. <i>Breast</i> , 2009, 18, 373-377.	0.9	58
85	Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: Outcome analysis from a single-institution prospectively collected database. <i>European Journal of Cancer</i> , 2009, 45, 2537-2545.	1.3	82
86	9318 Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease free and overall survival in clinical stage I-II AJCC skin melanoma—a prospective study. <i>European Journal of Cancer, Supplement</i> , 2009, 7, 582.	2.2	0
87	Axillary recurrence in sentinel lymph node negative breast cancer patients. <i>European Journal of Cancer, Supplement</i> , 2008, 6, 150.	2.2	0
88	Axillary recurrence in sentinel lymph node-negative breast cancer patients. <i>Annals of Oncology</i> , 2008, 19, 1842-1846.	0.6	23
89	Breast cancer follow-up: just a burden, or much more?. <i>Annals of Oncology</i> , 2007, 18, 1431-1432.	0.6	2
90	Tailoring a tailored treatment: the importance of fine-tuning on the patient. <i>Annals of Oncology</i> , 2005, 16, 683-685.	0.6	0

#	ARTICLE	IF	CITATIONS
91	Sentinel node biopsy in the surgical management of breast cancer: experience in a general hospital with a dedicated surgical team. <i>Breast</i> , 2004, 13, 200-205.	0.9	4
92	Adult acute myeloid leukaemia. <i>Critical Reviews in Oncology/Hematology</i> , 2004, 50, 197-222.	2.0	144
93	Adult acute lymphoblastic leukaemia. <i>Critical Reviews in Oncology/Hematology</i> , 2004, 50, 223-261.	2.0	79
94	Histiocyte disorders. <i>Critical Reviews in Oncology/Hematology</i> , 2004, 50, 157-174.	2.0	152
95	Population-based sentinel lymph node biopsy in early invasive breast cancer. <i>European Journal of Surgical Oncology</i> , 2004, 30, 618-623.	0.5	2
96	Pre-operative endocrine therapy for postmenopausal women: When and why?. <i>Annals of Oncology</i> , 2001, 12, 1505-1506.	0.6	3
97	Fludarabine and cladribine in relapsed/refractory low-grade non-Hodgkin's lymphoma: A phase II randomized study. <i>Annals of Oncology</i> , 2000, 11, 231-233.	0.6	32
98	Axillary sentinel node biopsy under local anaesthesia in early breast cancer. <i>Annals of Oncology</i> , 2000, 11, 1617-1618.	0.6	15
99	Diffuse Large-Cell Lymphoma of the Testis. <i>Journal of Clinical Oncology</i> , 1999, 17, 2854-2854.	0.8	82
100	Dose-escalation of CHOP in non-Hodgkin's lymphoma. <i>Annals of Oncology</i> , 1999, 10, 519-526.	0.6	28
101	PCR-based clonality analysis: a reliable method for the diagnosis and follow-up monitoring of conservatively treated gastric B-cell MALT lymphomas?. <i>Histopathology</i> , 1999, 34, 326-330.	1.6	34
102	START programme. <i>European Journal of Cancer</i> , 1999, 35, S387.	1.3	0
103	START: A European state-of-the-art on-line instrument for clinical oncologists. <i>Annals of Oncology</i> , 1999, 10, 769-774.	0.6	13
104	Stage-modified international prognostic index effectively predicts clinical outcome of localized primary gastric diffuse large B-cell lymphoma. <i>Annals of Oncology</i> , 1999, 10, 1433-1440.	0.6	42
105	Supporting tools for guideline development and dissemination. <i>Artificial Intelligence in Medicine</i> , 1998, 14, 119-137.	3.8	33
106	Role of endosonography in the management of patients with gastric malt lymphoma. <i>Gastroenterology</i> , 1998, 114, A683.	0.6	1
107	Initial chemotherapy for primary resectable large-cell lymphoma of the stomach. <i>Annals of Oncology</i> , 1997, 8, 497-499.	0.6	36
108	Lack of carboplatin activity in malignant lymphomas. <i>European Journal of Cancer</i> , 1996, 32, 2370-2371.	1.3	0

#	ARTICLE	IF	CITATIONS
109	Activity of single agent vinorelbine in pretreated non-Hodgkin's lymphoma. <i>Annals of Oncology</i> , 1996, 7, 970-972.	0.6	20
110	Combined modality treatment for primary gastrointestinal non-Hodgkin's lymphoma: The Milan Cancer Institute Experience. <i>Annals of Oncology</i> , 1993, 4, 831-837.	0.6	58
111	Combined modality treatment with primary CHOP chemotherapy followed by locoregional irradiation in stage I or II histologically aggressive non-Hodgkin's lymphomas.. <i>Journal of Clinical Oncology</i> , 1993, 11, 720-725.	0.8	98
112	Taxol administered as a 120 hour infusion. <i>Investigational New Drugs</i> , 1992, 10, 275-278.	1.2	48
113	Prognostic factors in non-Hodgkin's lymphoma. <i>Current Opinion in Oncology</i> , 1990, 2, 849-854.	1.1	0
114	Elevated CA125 levels in patients with metastatic breast carcinoma. <i>British Journal of Cancer</i> , 1990, 62, 668-670.	2.9	16
115	High-dose cytosine arabinoside in relapsed and refractory non-Hodgkin's lymphoma. Limited role as a single agent. <i>Cancer</i> , 1989, 64, 2014-2018.	2.0	5
116	Circulating Tumor Markers in Breast Cancer. <i>Hematology/Oncology Clinics of North America</i> , 1989, 3, 653-674.	0.9	27
117	Continuous Cisplatin Infusion in Combination with Vincristine and High-Dose Methotrexate for Advanced Osteogenic Sarcoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1987, 10, 152-155.	0.6	13
118	Long-term evaluation of surgery followed by adjuvant adriamycin in osteogenic sarcoma. <i>European Journal of Cancer & Clinical Oncology</i> , 1987, 23, 433-436.	0.9	12